Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK NAO Cancer Drug Fund Probe Curbed By Data Gaps

This article was originally published in Scrip

Executive Summary

England's Cancer Drug Fund (CDF) seems to have contributed to the use of innovative drugs in the UK but its actual impact on patient outcomes is unclear, due to lack of evidence, according to a study by Britain's National Audit Office (NAO).

You may also be interested in...



Ipsen’s Palovarotene Hit By FDA Clinical Hold

The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.

Freshly Funded ImCheck Goes After Gamma Delta T-Cells

ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.

Novartis Enters ‘Transformational’ Cloud Computing Pact With Amazon

Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.

Topics

UsernamePublicRestriction

Register

SC029801

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel